Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Martin Bergman

Rheumatology Ridley Park, PA Medical Doctor

NPI 1710977004 CMS profile 305128

23 W Chester Pike, Suite 201, Ridley Park, PA 19078

Open in the dashboard

General payments

$458,027

827 records reported · program years 2019–2024

Research payments

$16,006

Paid to them · 26 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Martin Bergman of Ridley Park, PA is reported in the CMS Open Payments database as having received $458,027 across 827 general payments and $16,006 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $6,057 3
2023 General $47,351 137
2022 General $50,269 155
2021 General $59,229 99
2021 Research $3,120 3
2020 General $87,565 82
2020 Research $8,266 13
2019 General $207,556 351
2019 Research $4,620 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martin Bergman
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Martin Bergman were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Martin Bergman Rheumatology median Middle half National median
2019 $207,556 $744 $153–$2,687 $163
2020 $87,565 $462 $98–$2,027 $114
2021 $59,229 $531 $101–$2,153 $132
2022 $50,269 $627 $125–$2,303 $149
2023 $47,351 $741 $145–$2,524 $160
2024 $6,057 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $130,058 211 payments
  2. Pfizer Inc. $76,789 78 payments
  3. Novartis Pharmaceuticals Corporation $71,452 76 payments
  4. Genzyme Corporation $24,491 35 payments
  5. Gilead Sciences, Inc. $22,408 30 payments
  6. Celgene Corporation $22,326 22 payments
  7. GlaxoSmithKline, LLC. $20,673 46 payments
  8. Regeneron Pharmaceuticals, Inc. $18,551 25 payments
  9. Amgen Inc. $18,308 72 payments
  10. E.R. Squibb & Sons, L.L.C. $15,680 54 payments
  11. Other $37,290 178 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200,879 74 payments
  2. Consulting Fee $165,570 59 payments
  3. Travel and Lodging $43,408 164 payments
  4. Honoraria $33,414 28 payments
  5. Food and Beverage $14,432 495 payments
  6. Education $325 7 payments
Products named General payments · program years 2019–2024
  1. COSENTYX $60,390 64 payments
  2. RINVOQ Immunology $59,266 78 payments
  3. HUMIRA $33,570 50 payments
  4. Otezla Dermatology $22,326 22 payments
  5. BENLYSTA $20,673 46 payments
  6. XELJANZ $20,668 35 payments
  7. Otezla Inflammation $17,199 26 payments
  8. KEVZARA $16,319 7 payments
  9. KEVZARA Rheumatology $12,205 12 payments
  10. RINVOQ Immunology $10,756 12 payments
  11. Other $63,257 398 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Amgen Inc. $6,439 10 payments
  2. Sanofi-Aventis U.S. LLC $3,439 10 payments
  3. Novartis Pharmaceuticals Corporation $3,360 3 payments
  4. Celgene Corporation $1,620 2 payments
  5. Genzyme Corporation $1,149 1 payment

Records

853 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record